We then examined the efficacy of triptolide to inhibit the growth of NSCLC cells in vitro and in vivo and if targeting of HA-CD44/RHAMM contributes to the growth inhibitory effects of the drug. The gene discussed is HMMR; the disease is non-small cell lung carcinoma.